(NASDAQ: APVO) Aptevo Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 48.9%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.87%.
Aptevo Therapeutics's earnings in 2025 is -$27,952,000.On average, 3 Wall Street analysts forecast APVO's earnings for 2025 to be -$243,718,805, with the lowest APVO earnings forecast at -$234,161,205, and the highest APVO earnings forecast at -$250,887,005. On average, 3 Wall Street analysts forecast APVO's earnings for 2026 to be -$127,531,279, with the lowest APVO earnings forecast at -$122,530,052, and the highest APVO earnings forecast at -$131,282,199.
In 2027, APVO is forecast to generate -$123,234,403 in earnings, with the lowest earnings forecast at -$118,401,681 and the highest earnings forecast at -$126,858,944.